Biotech Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients with Brain Glioblastoma Carrying BRAF V600 Mutation Bymedicilon September 1, 2023
Biotech Medicilon was selected into the SSE Science and Technology Innovation Board 100 Index, R&D intensity and revenue growth have been recognized Bymedicilon August 14, 2023
Biotech Medicilon interview with Dr. Xin Dong – In the field of immunotherapy, where the fierce competition is in full swing, where does Neologics Bioscience come from? Bymedicilon August 14, 2023
Biotech Fosun Health Capital reached a cooperation agreement with Medicilon to explore innovative drug research and development together Bymedicilon August 14, 2023
Biotech Medicilon Assists Yuyao Biotech’s STAT3 dual phosphorylation inhibitor YY201 has been approved for clinical trials Bymedicilon August 14, 2023
Biotech Medicilon Assisted – The IND application of BIOT-001, the first self-developed new drug of Biotime Biotechnology, was approved by the FDA Bymedicilon July 27, 2023
